- Raised $4.5M Undisclosed Round led by Cedars-Sinai Technology Ventures, Apr 2026
- Raised $1M grant, Mar 2025
- Raised Undisclosed Round led by Cedars-Sinai Accelerator, Sep 2024
About
iCardio.ai develops machine learning and deep learning algorithms for the analysis of ultrasound applications, with a specific focus on echocardiography (ultrasound of the heart). The company's mission is to revolutionize the way heart disease is detected and treated, improving outcomes for millions of individuals around the world. By providing accessible, accurate, and automated interpretation of cardiac imaging, iCardio.ai is democratizing quality cardiovascular health across the world. They partner with ultrasound companies to deliver their technology to clinicians and enterprises, aiming to integrate AI into cardiac imaging pipelines. iCardio.ai has received FDA 510(k) clearance for its artificial intelligence software for interpretation of echocardiography, including EchoMeasure™ for automated echo measurements and CardioVision™ for auto-detecting aortic stenosis.
Funding history · 4 rounds · $5.5M total
Headcount over time
Offices
Q&A
- What is iCardio.ai's primary focus?
- iCardio.ai develops AI for the interpretation of ultrasound imaging, specifically focusing on echocardiograms to detect and treat heart disease.
- What is iCardio.ai's mission?
- iCardio.ai's mission is to revolutionize the way heart disease is detected and treated by providing accessible, accurate, and automated interpretation of cardiac imaging, thereby democratizing quality cardiovascular health globally.
- What FDA clearances has iCardio.ai received?
- iCardio.ai has received FDA 510(k) clearance for its artificial intelligence software for echocardiography interpretation, including EchoMeasure™ for automated echo measurements and CardioVision™ for auto-detecting aortic stenosis.
- When was iCardio.ai founded?
- iCardio.ai was founded in 2019.
- Where is iCardio.ai headquartered?
- iCardio.ai is headquartered in Los Angeles, United States.
- Who are the co-founders of iCardio.ai?
- The co-founders of iCardio.ai include Joseph Sokol (CEO), Dr. Aakriti Gupta (Chief Medical Advisor), Dr. Roman Sandler (Chief Technology Officer), and Dr. Joshua Penn.
- What technologies does iCardio.ai utilize?
- iCardio.ai utilizes machine learning, deep learning, and AI technologies in its solutions.
- What are iCardio.ai's target customer segments?
- iCardio.ai targets clinicians, enterprises, and ultrasound companies as its customers.
Team · 30
Sectors & technology
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | icardio.ai |
|---|
Identifiers & details
| Founded | 2019 |
|---|---|
| Employees (exact) | 23 |
Radar intelligence
Patents
| EPO | 1 |
|---|
Web history (Wayback)
| Domain | icardio.ai |
|---|